TNF-alpha inhibitors for ankylosing spondylitis and non-radiographic axial spondyloarthritis

  • Technology appraisal guidance
  • TA383
  • Published: 

Review decision – March 2019

Decision to move the existing guidance to the static list

We would like to update you on the decision made regarding the review of the existing guidance on TNF-alpha inhibitors for ankylosing spondylitis and non-radiographic axial spondyloarthritis (TA383).

There is no new evidence to suggest the recommendations should change. The guidance has already been incorporated into the NICE guideline on spondyloarthritis in over 16s, published in February 2017.

NICE’s Guidance Executive has decided to proceed with this proposal without consultation.

Consequently, TA383 will move to the ‘static list’ of technology appraisals.

Review decision paper

Matrix of stakeholders

This page was last updated: